SCHEDULE: BlackRock Discloses 3.8% Stake in LB Pharmaceuticals

BlackRock Portfolio Management LLC has filed an amended Schedule 13G, reporting a 3.8% beneficial ownership stake in LB PHARMACEUTICALS INC.

Summary

• BlackRock Portfolio Management LLC beneficially owns 961,158 shares of LB PHARMACEUTICALS INC common stock.
• This ownership represents 3.8% of the total outstanding common stock of LB PHARMACEUTICALS INC.
• BlackRock Portfolio Management LLC holds sole voting power over 863,342 shares and sole dispositive power over 961,158 shares.
• No shared voting or dispositive power is reported.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership, providing no qualitative information to assess positive or negative sentiment regarding the issuer's performance or prospects.

Positives

• NA

Negatives

• NA

Risks

• NA

Future Outlook

NA

Management Comments

• "To the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This filing represents a routine disclosure of institutional ownership by BlackRock Portfolio Management LLC, a common practice in the financial industry for investment firms managing client assets. It reflects a passive investment stake below the 5% threshold, indicating no intent to influence the issuer's control.

Key Dates

Keywords

BlackRock, LB PHARMACEUTICALS, Schedule 13G, beneficial ownership, common stock, institutional investment, equity stake